<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/" xmlns:ynews="http://news.yahoo.com/rss/">
<channel>
<title>Yahoo! News: Business - Health Care Industry</title>
<copyright>Copyright (c) 2009 Yahoo! Inc. All rights reserved.</copyright>
<link>http://news.yahoo.com/i/2168</link>
<category>business</category>
<description>Business - Health Care Industry</description>
<language>en-us</language> 
<lastBuildDate>Thu, 26 Nov 2009 04:37:21 GMT</lastBuildDate>
<ttl>5</ttl> 
<image>
<title>Yahoo! News</title>
<width>142</width>
<height>18</height>
<link>http://news.yahoo.com/i/2168</link>
<url>http://l.yimg.com/a/i/us/nws/th/main_142b.gif</url>
</image>
<item>
<title>AP IMPACT: A stream of WH health care visits 
    (AP)
</title>
 <link>http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20091126/ap_on_bi_ge/us_white_house_health_meetings</link>
 <guid isPermaLink="false">ap/20091126/us_white_house_health_meetings</guid>
<source>AP</source>
<category>business</category>
<pubDate>Thu, 26 Nov 2009 04:37:21 GMT</pubDate>
<description>&#60;p>&#60;a href="http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20091126/ap_on_bi_ge/us_white_house_health_meetings">&#60;img src="http://d.yimg.com/a/p/ap/20091125/capt.478c866c864f40189ded1ba1926ad01f.white_house_health_meetings_wx104.jpg?x=130&amp;y=94&amp;q=85&amp;sig=3jpqgIX6Eud2PQkG15w8qQ--" align="left" height="94" width="130" alt="FILE - In this May 11, 2009 file photo, President Barack Obama, center, speaks about health care in the State Dining Room of the White House in Washington.  From left: Cedars-Sinai Health System President Thomas Priselac; Merck CEO Richard Clark; Kaiser Permanente CEO George Halvorson; Obama; American Medical Association President J. James Rohack; SEIU Healthcare chair Dennis Rivera; and Edwards Lifesciences CEO Michael Mussallem. (AP Photo/Charles Dharapak, FILE)" border="0" />&#60;/a>AP - President Barack Obama&#039;s top aides met frequently with lobbyists and health care industry heavyweights as his administration pieced together a national health care overhaul, according to White House visitor records obtained Wednesday by The Associated Press.&#60;/p>&#60;br clear="all"/></description>
<media:content url="http://d.yimg.com/a/p/ap/20091125/capt.478c866c864f40189ded1ba1926ad01f.white_house_health_meetings_wx104.jpg?x=130&amp;y=94&amp;q=85&amp;sig=3jpqgIX6Eud2PQkG15w8qQ--" type="image/jpeg" height="94" width="130"/>
<media:text type="html">&#60;p>&#60;a href="http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20091126/ap_on_bi_ge/us_white_house_health_meetings">&#60;img src="http://d.yimg.com/a/p/ap/20091125/capt.478c866c864f40189ded1ba1926ad01f.white_house_health_meetings_wx104.jpg?x=130&amp;y=94&amp;q=85&amp;sig=3jpqgIX6Eud2PQkG15w8qQ--" align="left" height="94" width="130" alt="photo" title="FILE - In this May 11, 2009 file photo, President Barack Obama, center, speaks about health care in the State Dining Room of the White House in Washington.  From left: Cedars-Sinai Health System President Thomas Priselac; Merck CEO Richard Clark; Kaiser Permanente CEO George Halvorson; Obama; American Medical Association President J. James Rohack; SEIU Healthcare chair Dennis Rivera; and Edwards Lifesciences CEO Michael Mussallem. (AP Photo/Charles Dharapak, FILE)" border="0"/>&#60;/a>&#60;/p>&#60;br clear="all"/></media:text>
<media:credit role="publishing company">(AP)</media:credit>
</item>
<item>
<title>La Jolla Pharma axes plan to dissolve company 
    (AP)
</title>
 <link>http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20091125/ap_on_bi_ge/us_la_jolla_pharma_options</link>
 <guid isPermaLink="false">ap/20091125/us_la_jolla_pharma_options</guid>
<source>AP</source>
<category>business</category>
<pubDate>Wed, 25 Nov 2009 21:56:44 GMT</pubDate>
<description>AP - La Jolla Pharmaceutical Co. said Wednesday its shareholders did not support a proposal to dissolve the company, and it will consider other options.</description>
</item>
<item>
<title>Par Pharma buys back &#36;30.8M in senior notes 
    (AP)
</title>
 <link>http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20091125/ap_on_bi_ge/us_par_pharma_senior_notes</link>
 <guid isPermaLink="false">ap/20091125/us_par_pharma_senior_notes</guid>
<source>AP</source>
<category>business</category>
<pubDate>Wed, 25 Nov 2009 17:31:35 GMT</pubDate>
<description>AP - Par Pharmaceuticals Cos. said Wednesday it bought &#36;30.8 million in senior notes through a tender offer.</description>
</item>
<item>
<title>Idera: Novartis deal ends, Merck pact extended 
    (AP)
</title>
 <link>http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20091125/ap_on_bi_ge/us_idera_pharma_partnerships</link>
 <guid isPermaLink="false">ap/20091125/us_idera_pharma_partnerships</guid>
<source>AP</source>
<category>business</category>
<pubDate>Wed, 25 Nov 2009 17:14:21 GMT</pubDate>
<description>AP - Idera Pharmaceuticals Inc. on Wednesday announced the end of a research partnership with Novartis AG, but said Merck &amp; Co. is extending its work with Idera for another year.</description>
</item>
<item>
<title>Blue Cross calls, mailers get NC lawmakers&#039; notice 
    (AP)
</title>
 <link>http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20091124/ap_on_bi_ge/us_xgr_blue_cross_advocacy</link>
 <guid isPermaLink="false">ap/20091124/us_xgr_blue_cross_advocacy</guid>
<source>AP</source>
<category>business</category>
<pubDate>Tue, 24 Nov 2009 23:19:54 GMT</pubDate>
<description>AP - State lawmakers and attorneys are scrutinizing Blue Cross and Blue Shield of North Carolina for its attempt to influence the national health care debate through direct mail and possibly illegal automated phone calls.</description>
</item>
<item>
<title>Kaiser Of Industry And Health 
    (Investor&#039;s Business Daily)
</title>
 <link>http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ibd/20091124/bs_ibd_ibd/20091124lands</link>
 <guid isPermaLink="false">ibd/20091124/20091124lands</guid>
<source>Investor&#039;s Business Daily</source>
<category>business</category>
<pubDate>Tue, 24 Nov 2009 23:07:34 GMT</pubDate>
<description>Investor's Business Daily - When he lost a big government contract to build the Shasta Dam in Northern California, he found a way to make the loss a win.</description>
</item>
<item>
<title>Valeant Pharma begins selling generic IBS drug 
    (AP)
</title>
 <link>http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20091123/ap_on_bi_ge/us_valeant_pharma_librax</link>
 <guid isPermaLink="false">ap/20091123/us_valeant_pharma_librax</guid>
<source>AP</source>
<category>business</category>
<pubDate>Mon, 23 Nov 2009 20:46:57 GMT</pubDate>
<description>AP - Valeant Pharmaceuticals said Monday it began selling a generic version of Librax, a treatment for irritable bowel syndrome drug.</description>
</item>
<item>
<title>Salix Pharmaceuticals completes stock offering 
    (AP)
</title>
 <link>http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20091123/ap_on_bi_ge/us_salix_pharmaceuticals_stock_offering</link>
 <guid isPermaLink="false">ap/20091123/us_salix_pharmaceuticals_stock_offering</guid>
<source>AP</source>
<category>business</category>
<pubDate>Mon, 23 Nov 2009 19:45:26 GMT</pubDate>
<description>AP - Salix Pharmaceuticals Ltd. said Monday it completed its public offering of 5.5 million shares of common stock.</description>
</item>
<item>
<title>Pharmasset: hepatitis C drug trial will continue 
    (AP)
</title>
 <link>http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20091123/ap_on_bi_ge/us_pharmasset_hepatitis_c</link>
 <guid isPermaLink="false">ap/20091123/us_pharmasset_hepatitis_c</guid>
<source>AP</source>
<category>business</category>
<pubDate>Mon, 23 Nov 2009 18:56:21 GMT</pubDate>
<description>AP - Pharmasset Inc. said Monday that it will continue enrolling patients in a clinical trial of RG7128, a drug that is designed to treat the liver disease hepatitis C.</description>
</item>
<item>
<title>Cigna, WellPoint upgraded on costs, reform details 
    (AP)
</title>
 <link>http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20091123/ap_on_bi_ge/us_wellpoint_mover</link>
 <guid isPermaLink="false">ap/20091123/us_wellpoint_mover</guid>
<source>AP</source>
<category>business</category>
<pubDate>Mon, 23 Nov 2009 18:08:32 GMT</pubDate>
<description>AP - An analyst for JPMorgan upgraded shares of WellPoint Inc. and Cigna Corp. Monday, saying the stocks should trade higher as the details of a federal health care reform bill come into focus.</description>
</item>
<item>
<title>Rigel shares rise on RBC analyst upgrade 
    (AP)
</title>
 <link>http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20091123/ap_on_bi_ge/us_rigel_mover</link>
 <guid isPermaLink="false">ap/20091123/us_rigel_mover</guid>
<source>AP</source>
<category>business</category>
<pubDate>Mon, 23 Nov 2009 17:53:31 GMT</pubDate>
<description>AP - Rigel Pharmaceuticals Inc. rose after an RBC Capital Markets analyst recommended buying shares of the drug developer based on his expectations the company will announce news of a partnership for a key drug candidate.</description>
</item>
<item>
<title>Raptor&#039;s genetic disorder drug meets study goals 
    (AP)
</title>
 <link>http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20091123/ap_on_bi_ge/us_raptor_pharmaceutical_study</link>
 <guid isPermaLink="false">ap/20091123/us_raptor_pharmaceutical_study</guid>
<source>AP</source>
<category>business</category>
<pubDate>Mon, 23 Nov 2009 16:05:21 GMT</pubDate>
<description>AP - Raptor Pharmaceutical Corp. said Monday its developing treatment for the genetic disorder nephropathic cystinosis met key goals in a midstage study.</description>
</item>
<item>
<title>Drugmaker Par Shapes A Base But Needs Time 
    (Investor&#039;s Business Daily)
</title>
 <link>http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ibd/20091120/bs_ibd_ibd/20091120basereader</link>
 <guid isPermaLink="false">ibd/20091120/20091120basereader</guid>
<source>Investor&#039;s Business Daily</source>
<category>business</category>
<pubDate>Fri, 20 Nov 2009 23:22:11 GMT</pubDate>
<description>Investor's Business Daily - Generic and branded drugmaker Par Pharmaceutical   notched a 52-week high in mid-October.</description>
</item>
<item>
<title>Big Pharma Mergers: Good News Or Bad? 
    (Investor&#039;s Business Daily)
</title>
 <link>http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ibd/20091120/bs_ibd_ibd/20091120health</link>
 <guid isPermaLink="false">ibd/20091120/20091120health</guid>
<source>Investor&#039;s Business Daily</source>
<category>business</category>
<pubDate>Fri, 20 Nov 2009 23:18:06 GMT</pubDate>
<description>Investor's Business Daily - Whoever says you can&#39;t throw money at problems hasn&#39;t spent much time following the Big Pharma sector this year.</description>
</item>
<item>
<title>BioCryst prices stock offering at &#36;9.75 per share 
    (AP)
</title>
 <link>http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20091120/ap_on_bi_ge/us_biocryst_pharmaceuticals_offering</link>
 <guid isPermaLink="false">ap/20091120/us_biocryst_pharmaceuticals_offering</guid>
<source>AP</source>
<category>business</category>
<pubDate>Fri, 20 Nov 2009 15:17:51 GMT</pubDate>
<description>AP - Flu drug developer BioCryst Pharmaceuticals Inc. priced its 5 million common stock share offering at &#36;9.75 per share.</description>
</item>
<item>
<title>Transparency Helps Benefits Manager Gain Clients 
    (Investor&#039;s Business Daily)
</title>
 <link>http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ibd/20091119/bs_ibd_ibd/20091119newamer</link>
 <guid isPermaLink="false">ibd/20091119/20091119newamer</guid>
<source>Investor&#039;s Business Daily</source>
<category>business</category>
<pubDate>Thu, 19 Nov 2009 23:13:28 GMT</pubDate>
<description>Investor's Business Daily - Pharmacy benefit management is a controversial industry. Yes, the industry saves health insurers on drug costs. But the giant pharmacy benefit managers, called PBMs, have also been the targets of multiple lawsuits claiming these middlemen earn outsize profits through opaque business practices.</description>
</item>
<item>
<title>FDA issues warnings to Web sites over drug sales 
    (AP)
</title>
 <link>http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20091119/ap_on_bi_ge/us_fda_illegal_pharmaceutical_sales</link>
 <guid isPermaLink="false">ap/20091119/us_fda_illegal_pharmaceutical_sales</guid>
<source>AP</source>
<category>business</category>
<pubDate>Thu, 19 Nov 2009 20:36:25 GMT</pubDate>
<description>AP - The Food and Drug Administration said Thursday it issued 22 warning letters to Web site operators over alleged illegal sales of unapproved or misbranded drugs.</description>
</item>
<item>
<title>Momenta rises on upgrade ahead of Lovenox ruling 
    (AP)
</title>
 <link>http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20091119/ap_on_bi_ge/us_momenta_pharma_mover</link>
 <guid isPermaLink="false">ap/20091119/us_momenta_pharma_mover</guid>
<source>AP</source>
<category>business</category>
<pubDate>Thu, 19 Nov 2009 18:31:04 GMT</pubDate>
<description>AP - Shares of Momenta Pharmaceuticals Inc. rose Thursday after an analyst upgraded the stock, saying Momenta will soon receive marketing approval for its version of the anti-clotting drug Lovenox.</description>
</item>
<item>
<title>Moody&#039;s gives negative view on pharma credit 
    (AP)
</title>
 <link>http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20091119/ap_on_bi_ge/us_pharma_ratings</link>
 <guid isPermaLink="false">ap/20091119/us_pharma_ratings</guid>
<source>AP</source>
<category>business</category>
<pubDate>Thu, 19 Nov 2009 18:30:38 GMT</pubDate>
<description>AP - Moody&#039;s Investors Service issued a negative opinion on the pharmaceutical industry Thursday, saying drugmaker credit ratings will be under pressure until early 2012 because they won&#039;t be able to fully replace revenue from best-sellers that go off-patent.</description>
</item>
<item>
<title>Ligand receives &#36;2 million from Merck partnership 
    (AP)
</title>
 <link>http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20091119/ap_on_bi_ge/us_ligand_pharmaceuticals_contract</link>
 <guid isPermaLink="false">ap/20091119/us_ligand_pharmaceuticals_contract</guid>
<source>AP</source>
<category>business</category>
<pubDate>Thu, 19 Nov 2009 18:23:22 GMT</pubDate>
<description>AP - Ligand Pharmaceuticals Inc. said Thursday it received a &#36;2 million milestone payment from Merck &amp; Co. as part of a research collaboration.</description>
</item>
</channel>
</rss>
<!-- server fe2.news.ac4.yahoo.com -->

